What Is Zenagamtide? Mechanism, Trial Status, and How It Compares With CagriSema

What is Zenagamtide?

Zenagamtide is a unimolecular dual agonist that activates both GLP-1 and amylin receptors. It was previously referred to as amycretin — the names refer to the same compound.

The key distinction: most dual-pathway obesity approaches combine two separate drugs (as CagriSema does with semaglutide plus cagrilintide). Zenagamtide attempts to deliver both GLP-1 and amylin activity from a single molecule. That difference has potential implications for dosing, manufacturing, and potentially tolerability — though these remain to be demonstrated in Phase 3 data. For a direct head-to-head breakdown, see our zenagamtide vs CagriSema comparison.

What Weight-Loss Data Has Zenagamtide Shown?

Novo Nordisk’s 2025 annual report states that Phase 2 results in type 2 diabetes showed weight loss of up to 14.5% after 36 weeks, with 89% of participants achieving HbA1c levels below 7%.

These figures come from type 2 diabetes Phase 2 work, not a completed Phase 3 obesity readout. Zenagamtide should be characterised as a high-conviction late-pipeline asset — not a proven market-ready obesity compound. Our CagriSema amylin and GLP-1 profile covers the more advanced combination approach targeting the same biology.

Why Is Zenagamtide Trending in 2026?

Novo Nordisk’s 2025 annual report and February 2026 investor presentation position zenagamtide as one of the company’s major follow-on assets in obesity and diabetes after semaglutide. The compound has now entered its Phase 3 REDEFINE programme for obesity — a critical inflection point that explains the surge in research and investor attention. Track all key trial milestones on our obesity drug approval tracker for 2026.

The question has shifted from what is this early asset? to could this become one of Novo’s next flagship obesity medicines? Explore our best research peptides 2026 guide for a wider view of the pipeline.

Is Zenagamtide the Same as CagriSema?

No. This is the most important distinction to understand.

CagriSema combines semaglutide (a GLP-1 agonist) and cagrilintide (an amylin analog) as two separate active components in a fixed-dose combination. Zenagamtide is a single molecule engineered to activate both GLP-1 and amylin pathways simultaneously.

They target the same biology through fundamentally different molecular architectures. That distinction matters for dosing flexibility, manufacturing complexity, and potentially tolerability and adherence. For context on how both compare with triple-agonist candidates, see our retatrutide vs tirzepatide vs CagriSema analysis.

What Still Needs to Be Proven?

Three open questions define the zenagamtide narrative heading into Phase 3:

1. Obesity efficacy at scale — Will Phase 3 weight-loss data match the mechanistic expectations?

2. Oral vs subcutaneous positioning — Will the two formulations target different populations or indications?

3. Unimolecular vs combination — Will a single-molecule approach compete effectively against CagriSema’s combination strategy?

Novo Nordisk’s Amycretin Pipeline — Phase III Programme & Development Timeline

SC Amycretin — Subcutaneous Phase III Trials

Novo Nordisk has confirmed that SC amycretin (the once-weekly subcutaneous amycretin formulation) is entering Phase III trials for obesity under the REDEFINE programme, with enrolment beginning Q1 2026. The Novo Nordisk Phase III programme for SC amycretin is expected to enrol thousands of patients with overweight or obesity across multiple global trial sites. The primary endpoint for these Phase III trials will likely mirror standard obesity drug development requirements: percentage change in body weight from baseline compared with placebo at 68 weeks.

The Danish drugmaker’s Phase III programme for amycretin represents one of the company’s largest pipeline investments. Novo Nordisk has demonstrated in Phase II that SC amycretin delivers clinically meaningful weight loss in patients with type 2 diabetes. The company now needs Phase III data to determine whether amycretin can compete against Eli Lilly’s tirzepatide and retatrutide for market share in the growing weight loss drug market. These Phase III trials will be tested across multiple dose levels of once-weekly subcutaneous amycretin.

Oral Amycretin — Oral Versions & Phase II Results

Novo Nordisk has also developed oral versions of amycretin, which completed Phase II study evaluation. The oral amycretin pill demonstrated weight loss in early results, positioning the company to pursue a dual-formulation strategy. Oral versions offer patients a non-injectable alternative that could expand access to amycretin treatment across populations who prefer a pill over subcutaneous injection. Novo Nordisk’s oral formulation is expected to enter its own Phase III programme for obesity, though the company has not confirmed exact timing.

The development of both SC amycretin and oral amycretin gives Novo Nordisk flexibility in how the drug ultimately reaches the market. Regulatory authorities typically review each formulation separately, meaning the company could launch the subcutaneous version first while the oral pill completes Phase III. This phased launch strategy has been successfully demonstrated by Novo Nordisk with semaglutide (Ozempic injection followed by Rybelsus oral pill).

Clinical Trials & Phase III Data Expectations

Phase II Study Results — What Amycretin Has Demonstrated

In the Phase II study, SC amycretin was tested over 36 weeks in patients with type 2 diabetes and overweight or obesity. The trial demonstrated weight loss of up to 14.5% from baseline, with the vast majority of participants reaching the primary endpoint of HbA1c below 7%. These Phase II results were reviewed favourably by the investment community and positioned amycretin as a serious competitor in the weight loss drug development pipeline.

The clinical trials also assessed safety: the most common adverse events reported with amycretin were gastrointestinal in nature, consistent with the GLP-1 receptor agonist drug class. The severity of common adverse events was generally mild to moderate, and most gastrointestinal effects decreased over the first 8–12 weeks of treatment as patient tolerability improved. Novo Nordisk reported that fewer patients discontinued amycretin compared with placebo-controlled trial arms of similar weight loss drugs.

Phase III Trials — Primary Endpoint & Regulatory Requirements

For the Phase III programme, regulatory authorities including the FDA and EMA will require Novo Nordisk to demonstrate that amycretin produces statistically significant weight loss compared with placebo in patients with obesity or overweight with at least one weight-related comorbidity. The primary endpoint in Phase III obesity trials is typically percentage body weight change from baseline at week 68 compared to placebo. The company must also demonstrate an acceptable safety profile across a larger patient population to determine the drug’s overall benefit-risk balance.

Investor expectations for Novo Nordisk’s Phase III amycretin trials are high. Analysts expect SC amycretin to demonstrate weight loss exceeding 20% at the highest doses tested, based on early results from the Phase II study and the compound’s dual mechanism of action. If amycretin achieves higher efficacy than semaglutide in Phase III, it could reshape the competitive landscape and capture significant market share for Novo Nordisk in the weight loss drug market.

Novo Nordisk, Market Competition & the Weight Loss Drug Landscape

Sales Projections & Market Access

The obesity drug market is projected to exceed USD 100 billion in annual sales by 2030, and Novo Nordisk is positioning amycretin to capture a significant share. The company currently dominates GLP-1 receptor agonist sales through Ozempic and Wegovy, but faces growing competition from Eli Lilly’s tirzepatide (Mounjaro/Zepbound) and an expanding pipeline of next-generation drugs. Access to obesity treatment remains a challenge globally, with insurance coverage limitations and high out-of-pocket costs restricting the market to a fraction of eligible patients with overweight or obesity.

Novo Nordisk’s amycretin launch timing could be critical. If SC amycretin receives regulatory approval, the company could launch the drug by 2028–2029, entering a market where multiple new weight loss drugs are expected to compete. The Danish drugmaker’s established manufacturing, distribution, and commercial infrastructure gives the company a significant advantage in bringing the drug to market quickly. Novo Nordisk has also signalled that pricing and access strategies will be central to the amycretin launch to expand treatment access beyond current GLP-1 patient populations.

Amycretin vs Competing Pipeline Compounds

Amycretin faces competition from several pipeline drugs in Phase III development. Pfizer, Roche, and Viking Therapeutics are all developing oral or injectable weight loss drugs that could launch in a similar timeframe. Compared with CagriSema (Novo Nordisk’s own combination drug), SC amycretin offers a simpler single-molecule approach. Compared with Eli Lilly’s retatrutide, amycretin targets different receptor pathways (GLP-1/amylin vs GLP-1/GIP/glucagon), making direct efficacy comparisons difficult until head-to-head trials are conducted.

The competitive review of Novo Nordisk’s pipeline shows that the company is hedging its obesity strategy across multiple compounds: semaglutide (established market leader), CagriSema (combination approach), and amycretin (unimolecular approach). This diversified development pipeline ensures Novo Nordisk maintains relevance regardless of which molecular approach ultimately demonstrates the highest efficacy and best safety profile in Phase III trials.

How Amycretin Works in the Brain & Body — Treatment Mechanism

Amylin Receptor Agonist Activity in the Brain

Zenagamtide’s amylin receptor agonist activity targets satiety centres in the brain, particularly the area postrema and nucleus tractus solitarius. These brain regions regulate appetite and food intake. By activating amylin receptors in the brain alongside GLP-1 receptors, the drug produces dual appetite suppression that has demonstrated greater weight loss than GLP-1 receptor agonist treatment alone. The amylin receptor agonist component also affects gastric emptying and insulin secretion, providing additional metabolic benefits.

Insulin regulation is another key treatment effect of amycretin. The GLP-1 receptor agonist activity enhances glucose-dependent insulin secretion, improving blood sugar control in patients with type 2 diabetes. This dual treatment mechanism—combining appetite suppression through the brain with improved insulin sensitivity peripherally—explains why the drug has demonstrated weight loss alongside substantial HbA1c reductions in clinical trials lasting 36 weeks.

Patient Selection & Treatment Considerations

Patients most likely to benefit from amycretin treatment include adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidaemia. The drug is being tested as a once-weekly subcutaneous injection, which offers convenience compared with daily dosing. Novo Nordisk will need to determine through Phase III trials which patients respond best to amycretin treatment, the optimal week of dose titration, and whether the drug’s safety profile remains favourable across half or more of the trial population exposed to the highest dose.

As amycretin moves through development toward expected launch, the company will also need to establish treatment guidelines, dosing protocols, and long-term safety monitoring programmes. The review of Phase III data by regulatory authorities will determine whether amycretin receives approval for obesity, type 2 diabetes, or both indications—a decision that will significantly affect market access, sales potential, and the company’s overall competitive position in the weight loss drug market.